4.6 Article

Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment

Journal

SUPPORTIVE CARE IN CANCER
Volume 31, Issue 6, Pages -

Publisher

SPRINGER
DOI: 10.1007/s00520-023-07852-x

Keywords

Taxane-associated acute pain syndrome; Docetaxel; Dexamethasone; Dose-dependent; Arthralgia; Myalgia

Ask authors/readers for more resources

This study aimed to investigate whether dexamethasone dosage can prevent taxane-associated acute pain syndrome (T-APS) in breast cancer patients. The results showed that a higher dose of dexamethasone significantly lowered the incidence and severity of T-APS.
PurposeTaxane-associated acute pain syndrome (T-APS) is one of the most bothersome adverse effects caused by taxanes. We have previously reported the attenuating effect of dexamethasone (DEX) on T-APS and its risk factors under DEX prophylaxis. However, the appropriate DEX dosage administration remains unclear. Therefore, this study aimed to investigate whether DEX dose-dependently prevents T-APS in breast cancer patients.MethodsWe retrospectively evaluated patients with breast cancer who received docetaxel (75 mg/m(2))-containing chemotherapy without pegfilgrastim and regular non-steroidal anti-inflammatory drugs. The patients were divided into 4 mg/day and 8 mg/day DEX groups, with each DEX dosage on days 2-4 (n = 68 for each group). Primary endpoint was the comparison of all-grade T-APS incidence between the groups. Propensity score-matching was performed to adjust the baseline factors between the groups, and outcomes in the matched-population were also assessed.ResultsThe incidence of all-grade T-APS was 72.1% in 4 mg/day group and 48.5% in 8 mg/day group, which was significantly lowered by higher DEX dosage (P = 0.008). The severity of T-APS was also significantly reduced in 8 mg/day group (P = 0.02). These results were confirmed in the propensity score matching. Multivariate logistic analysis showed that higher DEX dosage was an independent T-APS preventive factor, whereas age < 55 years was a risk factor. Moreover, DEX-dosage-associated adverse effects similarly appeared in both groups.ConclusionOur study suggested that DEX dose-dependently prevents T-APS in breast cancer treatment. As understanding of the nature of T-APS and its appropriate management can significantly contribute to less onerous chemotherapy provision, further studies are required.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available